Medical devices company Biocomposites has acquired a minority stake in UK-based Renovos Biologics, for an undisclosed sum.

Renovos has developed a synthetic, biodegradable nanoclay carrier called RENOVITE, which intends to place several pharmaceutical drugs and biologics at the treatment site.

A 23-gauge cannula is utilised for injecting this carrier to support minimally invasive procedures. It will transform into a stiff gel after it gets in contact with physiological fluids such as blood serum.

As a cell-responsive carrier, it expedites healing with a reduced dose of the therapeutic drug.

Renovos will obtain access to Biocomposites’ expertise and knowledge in drug carrier development to advance RENOVITE towards pre-market approval as a carrier for orthopaedic, spine and trauma applications.

Renovos Biologics CEO Dr Agnieszka Janeczek said: “We have long believed in the potential of RENOVITE to overcome the challenges in tissue regeneration by providing unprecedented retention of therapeutics at the site of repair.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, Biocomposites CEO Michael Harris will join the board of directors of Renovos.

Harris said: “The potential for RENOVITE as a next-generation drug carrier that can enhance the activity of therapeutic drugs at lower doses, whilst giving the surgeon much greater freedom to use in minimally invasive procedures, is very exciting.

“Following on from our recent acquisition of Artoss in June this year and Subiton and Synimed last year, Biocomposites has established itself as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue.”

Last month, Biocomposites acquired German bone graft substitutes manufacturer Artoss. The company offers NanoBone technology, which can be used as a synthetic degradable bone graft substitute.